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 Influenza is a viral respiratory illness with higher activity in the colder months. It is 
estimated that across the United States, 9,000,000 to 45,000,000 people become ill with 
influenza and 12,000 to 60,000 die due to influenza each year. There is a yearly vaccine for 
influenza available beginning at the start of each influenza season. 
 Children are at especially higher risk of becoming infected and transmitting influenza due 
to their under-developed immune systems and their general lack of good hand hygiene practices. 
Children with chronic diseases, like inflammatory bowel disease (IBD), are especially vulnerable 
to dangerous complications from influenza due to their disease and treatment. Therefore, 
children with chronic diseases are a target group for influenza vaccine efforts. Childhood 
immunization coverage has been examined in many countries and groups of children for many 
vaccines. However, influenza vaccination coverage and predictors of vaccination have not been 
analyzed in children with IBD. 
 To examine influenza vaccine coverage in children with IBD, data from South Carolina 
Medicaid was analyzed to identify vaccination patterns over time and predictors and barriers of 
vaccination in children with and without IBD in South Carolina. 1,184 children with IBD and 
4,736 children without IBD were included. 
This project provides more information about the universal topic of vaccine coverage 
among children. The project analyzes vaccination coverage for an important illness among a 
vulnerable group of children. This project demonstrates that influenza vaccination coverage in all 
children is increasing over time in children in South Carolina and that disparities in influenza 
vaccination coverage exist among certain groups of children. 
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Introduction: Children with chronic health conditions, including IBD, are at especially high risk 
for influenza infection and resulting complications. The Crohn’s & Colitis Foundation’s Top 10 
Quality Process Indicators for IBD and American College of Gastroenterology’s clinical 
guidelines for preventative health maintenance recommend that IBD patients should receive 
annual influenza vaccination. The aims of this study were to evaluate influenza vaccination 
coverage over time and identify predictors of influenza vaccination in pediatric IBD and non-
IBD patients. 
Methods: We utilized longitudinal data (2001 to 2016) from South Carolina Medicaid to 
conduct a matched cohort study. The primary exposure of interest was diagnosis of IBD based 
upon ICD-9/10 diagnosis codes. The included subjects were eligible for SC Medicaid at least 9 
months out of 12 each year and had no months of ineligibility occurring between October and 
May. Children with IBD were matched 1:4 to children without IBD on age and sex. Influenza 
vaccination coverage for IBD and non-IBD groups for each season were calculated as [# 
receiving vaccine] / [# eligible]. We calculated 95% confidence intervals for these estimates 
using 10,000 nonparametric bootstrap replications adjusted for clustering. A multivariable 
random effects logistic regression model was used to identify predictors of influenza vaccination. 
Results: Overall, 1,184 IBD subjects and 4,736 matched non-IBD subjects were identified 
during the study period. Among the IBD patients, 698 were diagnosed with ulcerative colitis, 
348 were diagnosed with Crohn’s disease, and 138 patients had diagnosis codes for both. The 
average age was 9.5 years and the majority of patients were male (52.7%). Among pediatric IBD 
patients, influenza vaccination coverage increased from 2% in 2001 to 40% in 2016. Children 
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with IBD, children residing in urban zip codes, white females, and children receiving 
corticosteroids had higher odds of obtaining an influenza vaccination. 
Conclusion: Influenza vaccination coverage for both pediatric IBD and non-IBD patients 
significantly increased from 2001 to 2016. Disparities in influenza vaccination coverage were 
identified among black patients and patients living in rural zip codes. IBD patients were more 
likely to get vaccinated compared to non-IBD patients, although vaccination coverage in SC 
remains below target levels. Overall, efforts to increase influenza vaccination in pediatric IBD 




















Most adults who become infected with influenza recover within two weeks. Children, 
however, particularly children younger than five years old and especially children under two 
years old, have an increased risk for developing complications from influenza infection. Children 
with chronic health conditions, including inflammatory bowel disease (IBD), are at especially 
high risk for influenza infection and resulting complications.
1
 Serious complications of influenza 
include pneumonia, myocarditis, rhabdomyolysis, encephalitis, and multiple-organ failure.
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Pediatric patients are both at higher risk of contracting influenza and of spreading it. Therefore, 
influenza vaccination is especially important in pediatric patients because of their high 
susceptibility. A study from July 2010 through June 2014 found that influenza vaccination 
reduces the risk of influenza-associated death in pediatric patients.
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IBD includes Crohn’s disease and ulcerative colitis. The specific pathologies of these two 
conditions share some characteristics; both diseases involve chronic inflammation of the 
gastrointestinal tract in varying areas and degrees of severity.
4
 Studies suggest that IBD is at least 
partially caused by an impaired immune response to environmental and/or infectious factors.
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Research has been focused on finding specific genetic markers of IBD that are linked with 
activity of the immune system.
6
 Through the genome-wide association study, specific genetic 
loci associated with IBD and the immune system have been found. There are immune deficiency 
genes associated with both Crohn’s disease and ulcerative colitis.
7
 Therefore, IBD patients are 
known to have an impaired immune system by nature of the disease which may make them more 
susceptible to viral infections, including influenza. 
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The Crohn’s Colitis Foundation has published the Top 10 Quality Process Indicators for 
IBD which recommends annual influenza vaccination to IBD patients on immunosuppressive 
medications.
8
 The American College of Gastroenterology also has a list of clinical guidelines for 
preventative health maintenance which states that IBD patients should receive annual influenza 
vaccination.
9
 Despite those recommendations, limited evidence suggests that influenza 
vaccination in IBD patients may be suboptimal. A study from Canada indicated that 10% of 
pediatric IBD patients had incomplete childhood immunizations. IBD-related reasons for 
incomplete vaccination included use of immunosuppressant medications and disease flare up at 
the time of immunization.
10
 However, this was only a snapshot, and the change in vaccination 
patterns over time was not assessed. Similarly, a Polish study found that children with IBD were 
two times less likely to receive the annual influenza vaccine than controls.
11
 Additionally, a 
French survey study found that only 22% of IBD pediatric patients had received annual influenza 
vaccination in 2011.
12
 Therefore, it is likely that children with IBD have poor influenza 
vaccination coverage. 
 This research was completed with support from the Crohn’s & Colitis Foundation 
Student Research Award Grant. The aims of this study were to evaluate influenza vaccination 











We utilized longitudinal data (2001 to 2016) from South Carolina Medicaid to conduct a 
matched cohort study. The primary exposure of interest was diagnosis of IBD based upon 
International Statistical Classification of Diseases and Related Health Problems (ICD-9/10) 
diagnosis codes. The diagnosis codes used are listed in the Appendix. The included subjects were 
eligible for SC Medicaid at least 9 months out of 12 each year and had no months of ineligibility 
occurring between October and May. Children with IBD were matched 1:4 to children without 
IBD on age and sex. 
We analyzed differences in characteristics between IBD and non-IBD patients as well as 
between patients with Crohn’s disease, ulcerative colitis, and indeterminate IBD (patients who 
had ICD-9/10 codes for both diseases). We also analyzed medication use by patient-years in 
patients with Crohn’s disease, ulcerative colitis, and indeterminate IBD. The medications 
identified by class are listed in the Appendix. Influenza vaccination coverage for IBD and non-
IBD groups for each season were calculated as [# receiving vaccine] / [# eligible]. The billing 
codes used to identify influenza vaccination are listed in the Appendix. We calculated 95% 
confidence intervals for these estimates using 10,000 nonparametric bootstrap replications 
adjusted for clustering. A multivariable random effects logistic regression model was used to 
identify predictors of influenza vaccination. All analyses were calculated using Stata/MP, 








  Overall, 1,184 IBD subjects and 4,736 matched non-IBD subjects were identified during 
the study period. The average age was 9.5 years and the majority of patients were male (52.7%). 
The characteristics of the IBD and matched non-IBD patients are listed in Table 1.  
 
Table 1: Characteristics of IBD and Non-IBD Patients 





Age, years 6.85 6.38 <0.01 
Male, % 52.7 52.7 >0.05 
Race, %       
   White 47.13 37.01 >0.001 
   Black 34.84 50.12 >0.001 
   Other 18.02 21.88 >0.001 
Zip Code, %       
   Rural 31.93 35.56 0.019 
   Urban 68.07 64.44 0.019 
  
 
Among the IBD patients, 698 were diagnosed with ulcerative colitis, 348 were diagnosed 
with Crohn’s disease, and 138 patients had diagnosis codes for both. The characteristics of the 









Table 2: Characteristics of IBD Patients by Disease 








Age, years 9.30 9.45 10.90 
Male, % 54.09 50.29 51.45 
Race, %     
 
   White 46.25 50.64 42.52 
   Black 36.09 29.62 41.73 
   Other 17.66 19.75 15.75 
Zip Code, %     
 
   Rural 36.50 25.64 34.41 
   Urban 63.50 74.36 65.59 
†
Patients had ICD-9/10 codes for both diseases. 
 
 
In patients with ulcerative colitis and Crohn’s disease, corticosteroids were used most 
frequently. In patients with indeterminate IBD, aminosalicylates (5-ASA’s) were used most 
frequently. The medication use among IBD patients is listed in Table 3. 
 
Table 3: Medication Usage Among IBD Patients by Person-Years of 
Observation 





Total P-Y 5,035 2,410 1,087 
IBD Drugs, P-Y of use (%) 
   5-ASAs 403 (8) 196 (8.13) 396 (36.43) 
   Immuno- 
   suppressants 255 (5.06) 76 (3.15) 192 (17.66) 
   Biologics 35 (0.7) 3 (0.12) 50 (4.6) 
   Corticosteroids 576 (11.44) 310 (12.86) 251 (23.09) 
Influenza Vaccine, 
P-Y (%) 1,071 (21.27) 560 (23.24) 223 (20.52) 
†




Compared to non-IBD subjects, children with IBD had higher odds of obtaining an 
influenza vaccination (OR=1.22, p<0.001). Children residing in urban locations had higher odds 
of obtaining an influenza vaccination (OR=1.56, p=0.001) compared to children from rural 
locations. Compared to white females, black females (OR=0.85, p=0.017) and black males 
(OR=0.84, p=0.012) had significantly lower odds of obtaining an influenza vaccination. Children 
receiving corticosteroids had higher odds of obtaining an influenza vaccination (OR=1.21, 
p<0.001) compared to children not receiving corticosteroids. The identified predictors of 
influenza vaccination are listed in Table 4. 
 
Table 4: Predictors of Influenza Vaccination 
  Odds Ratio 95% CI p-value 
Birth Year 1.24 1.23-1.25 <0.001 
IBD Diagnosis 1.22 1.10-1.36 <0.001 
Age 0.90 0.89-0.91 <0.001 
Race & Sex       
   White Female 1.0 - -  
   Black Female 0.85 0.74-0.97 0.017 
   Other Female 1.26 1.03-1.53 0.023 
   White Male 0.94 0.82-1.08 >0.05 
   Black Male 0.84 0.74-0.96 0.012 
   Other Male 1.20 1.03-1.41 0.023 
 Zip Code     
   Rural 1.0 - -  
   Urban 1.56 1.42-1.71 <0.001 
Corticosteroid Use 1.21 1.08-1.36 <0.01 
 
 
Among pediatric IBD patients, influenza vaccination coverage increased from 2% in 
2001 to 40% in 2016. For each year into the study, children had higher odds of obtaining an 
influenza vaccination (OR=1.24, p<0.01). Influenza vaccination over time is shown in Figure 1.  
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Figure 1: Influenza Vaccination Over Time 
 
†
Advisory Committee on Immunization Practices (ACIP) recommendations are shown in boxes. 
††

















Predictors of influenza vaccination included IBD diagnosis, later birth year, an urban zip 
code, corticosteroid use, and patients of other (non-white and non-black) races of both sexes. 
This project identified potential target groups for increased vaccination efforts; disparities in 
influenza vaccination coverage were identified among black patients and patients living in rural 
zip codes. 
Influenza vaccination coverage for both pediatric IBD and non-IBD patients significantly 
increased from 2001 to 2016. However, even the latest data from 2016 showed that less than 
50% of patients are getting vaccinated. IBD patients were more likely to get vaccinated 
compared to non-IBD patients, although influenza vaccination coverage in South Carolina 
remains below target levels. SC ranks lower than the national average in other childhood 
vaccines such as measles, mumps, rubella; Haemophilus influenzae type b; birth dose of hepatitis 
B; and both hepatitis A doses.
18
 This project has shown that efforts to increase influenza 
vaccination in both pediatric IBD and non-IBD patients are needed. 
The strengths of this study include the use of data from the entire state of South Carolina 
and the use of a control group. Some limitations of this study include the small sample size and 
the lack of information about severity of disease. Also, some patients may have lost Medicaid 
coverage and re-enrolled in Medicaid later, so some years of data may have been lost for some 
patients. Also, some patients may have received vaccination through the Centers for Disease 




Further studies could be completed to find interventions to increase vaccination coverage 
in target populations, including IBD pediatric patients. Also, further research to identify and 
analyze health outcomes associated with influenza vaccination in IBD pediatric patients is 
needed. 
In conclusion, the data from this study demonstrate that vaccination rates remain below 
target levels among all pediatric patients in South Carolina. Overall, efforts to increase influenza 
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Salicylates – AHFS code 28:08.04.24 
 Sulfasalazine (Azulfidine®, Azulfidine EN®) – 28:08.04.24 
 Mesalamine suppository (Rowasa®) – 28:08.04.24, 56:36 
 Mesalamine enema (Canasa®) – 28:08.04.24, 56:36 
 Mesalamine oral (Asacol HD®, Apriso®, Lialda®, Pentasa®, Delzicol®) – 28:08.04.24, 
56:36 
 Olsalazine (Dipentum®) – 28:08.04.24 
 Balsalazide (Colazal®) – 28:08.04.24 
Immunosuppressants (antimetabolites) – AHFS code 92:44 
 Azathioprine (Imuran®, Azasan®) – 92:44 
 Cyclosporine (Gengraf®, Neoral®, Sandimmune®) – 92:44 
 Mercaptopurine (Purinethol®) – 92:44, 10:00 
 Methotrexate (no branded IM injection) – 92:36, 10:00 
Monoclonal Antibodies – AHFS code 8:18.24 
 Adalimumab (Humira®) – 8:18.24, 56:92, 92:20, 92:36 
 Cetolizumab (Cimzia®) – 8:18.24, 56:92, 92:36, 92:36 
 Infliximab (Remicade®, Inflectra®, Renflexis®, Ixifi®) – 8:18.24, 56:92, 92:20, 92:36 
 Natalizumab (Tysabri®) – 8:18.24, 56:92, 92:20, 92:36 
 Vedolizumab (Entyvio®) – 8:18.24, 56:92, 92:20, 92:36 
 Golimumab (Simponi®) – 8:18.24, 56:92, 92:20, 92:36 
Corticosteroids (adrenals) – AHFS code 84:06.08 
 Budesonide (Enterocort EC®, Uceris®) – 84:06.08, 68:04 
 Prednisone (Deltasone®, Rayos®, Sterapred®) – 84:06.08, 68:04 
 Methylprednisolone (Medrol®) – 84:06.08, 68:04 
 Hydrocortisone (Cortef®) – 84:06.08, 68:04 
 Dexamethasone (Decadron®) – 84:06.08, 68:04 
 
 
HCPCS Codes for Influenza Vaccination 
 
 Q2034-Q2039 























 Ulcerative Colitis – 555.xx 
 Crohn’s Disease – 556.xx 
 Influenza – 487.xx, 488.xx 





 Ulcerative Colitis – K51.xx 
 Crohn’s Disease – K50.xx 
 Influenza – J09.xx, J10.xx, J11.xx 
 Influenza vaccine –  Z23 
 
